Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration

J Med Chem. 2018 Sep 27;61(18):8078-8087. doi: 10.1021/acs.jmedchem.8b00370. Epub 2018 Jun 4.

Abstract

Dual leucine zipper kinase (DLK, MAP3K12) is an essential driver of the neuronal stress response that regulates neurodegeneration in models of acute neuronal injury and chronic neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. In this review, we provide an overview of DLK signaling mechanisms and describe selected small molecules that have been utilized to inhibit DLK kinase activity in vivo. These compounds represent valuable tools for understanding the role of DLK signaling and evaluating the potential for DLK inhibition as a therapeutic strategy to prevent neuronal degeneration.

Publication types

  • Review

MeSH terms

  • Animals
  • Calcium-Binding Proteins
  • Humans
  • Intercellular Signaling Peptides and Proteins
  • MAP Kinase Kinase Kinases / antagonists & inhibitors*
  • Membrane Proteins / antagonists & inhibitors*
  • Neurodegenerative Diseases / drug therapy*
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Calcium-Binding Proteins
  • DLK1 protein, human
  • Intercellular Signaling Peptides and Proteins
  • Membrane Proteins
  • Protein Kinase Inhibitors
  • MAP Kinase Kinase Kinases
  • mitogen-activated protein kinase kinase kinase 12